
VRCA Stock Forecast & Price Target
VRCA Analyst Ratings
Bulls say
Verrica Pharmaceuticals Inc. has demonstrated significant growth in the volume of dispensed applicator units, with a notable 29% increase in Q3 2024 compared to Q2 2024, and a sustained 12% growth in Q4 2024, reaching 8,654 units which translated to approximately $5.9 million in sales. The company's efforts to normalize inventory levels are expected to enhance the alignment between product availability and consumer demand, potentially boosting future sales performance. Additionally, despite recent cost restructuring and a downsized sales force, the upward trend in dispensed units suggests a resilient market demand that could benefit the company in the upcoming quarters.
Bears say
Verrica Pharmaceuticals faces significant challenges due to competition from cheaper treatment options available in the market, which could hinder product pricing and payor coverage for its treatments. The company reported a substantial loss of $16.2 million in the fourth quarter of 2024, raising concerns about its financial viability and the need for additional funding for operations and debt repayment. Furthermore, uncertainties surrounding the clinical trials of its product candidate, Ycanth, coupled with potential supply chain disruptions, add to the risks affecting its growth prospects and overall business stability.
This aggregate rating is based on analysts' research of Verrica Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
VRCA Analyst Forecast & Price Prediction
Start investing in VRCA
Order type
Buy in
Order amount
Est. shares
0 shares